Also of interest, a phase I/II trial is evaluating HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with previously treated, locally advanced or metastatic solid tumors, including GC, which are HER2 amplified or overexpressed (NCT04650451). The gene discussed is ERBB2; the disease is gastric cancer.